Innovation in Biological Indicator Evaluator Resistometer Vessel Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovation in Biological Indicator Evaluator Resistometer Vessel Technology
The authors examine advances in the design and the application of biological indicator evaluator resistometer vessels used to measure the resistance of bacterial spores in monitoring sterilization processes.


Pharmaceutical Technology



Figure 8
Fedegari. During the insertion and removal of the BI cassette, a slight temperature drop in the chamber was recorded. The effect is more pronounced when operating at higher temperatures, but in all cases, the temperature dropped no lower than the set point minus 0.5 C. The maximum and minimum temperatures recorded during a 121 C and a 129 C cycle are displayed in Figure 6. Figure 7 displays the same 121 C data at a higher resolution. These figures represent the typical performance of the resistometer. Pressure readings in all cycles corresponded with the temperature readings, indicating that saturated steam was present in the chamber.


Table III. Survivor-curve D-values collected in triplicate on spore strip lot S1.


Figure 9
Steris resistometers. Both Steris resistometers operated as described in the ISO standard. The temperature recording from a 121 C cycle is shown in Figure 8. Fedegari data from Figure 3 also are presented for comparison purposes.


Figure 10
Survivor curve: spore strip. Survivor-curve data collected on the spore-strip lot S1 are shown in Table III. In the Fedegari, D-values were calculated to be 2.7 min in all three trials. In the Steris resistometer, D-values ranged from 2.3 min to 2.8 min (see Figures 9 and 10).


Table IV. Fraction negative D-values collected on spore strip BI lot S1 in three resistometers.
Fraction negative: spore strip. Fraction-negative data collected on the spore strip lot S1 are presented in Table IV. In all three resistometers, D 121-values were 1.5 min.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here